As the industry continues to externalize components of the supply chain, global regulatory authorities are requiring a “quality-by-design” (QbD) approach to help mitigate risk across the drug development process.
Teewinot’s Irish subsidiary has been granted a fourth patent for a pharmaceutical cannabinoid manufacturing technique which it says saves both time and money.
Ipca Laboratories has added scale to the Phase II support services offered by recent acquisition Onyx Scientific in a bid to build in the US contract manufacturing sector.
Sartorius Stedim Biotech (SSB) has launched a new small-scale bioreactor citing growing biopharmaceutical company demand for scale-up technologies as the key driver for its development.
Pall and New Brunswick have teamed up to develop and supply new disposable bioreactor technologies, targeting growing demand for products that improve quality and reduce cost of biomanufacturing.
Xcellerex is building a second cGMP FlexFactory biomanufacturing facility to support clients transitioning to their own plants and provide contract manufacturing services.
Microfluidics chose Interphex 2010 in New York, US to unveil a new processing technology that it claims can help manufacturers save time and money by switching from batch to continuous particle production.
SAFC Biosciences hopes Ex-Cell Antifoam, its new foam control product for cell culture bioreactors, will work the biomanufacturing sector into a lather.
Rottendorf Pharma has completed its development and upscaling pilot plant, which will complement its other sites that provide manufacturing and packaging services.
Flexibility is going to be a key driver for the pharmaceutical market in the next few years, according to Millipore's VP of downstream processing Paul Chapman.
US contract manufacturer Ash Stevens Inc has upgraded its active pharmaceutical ingredient (API) facility in Riverview, Michigan, with new equipment for parallel synthesis and calorimetry.
Failure to get it right in designing and implementing a
manufacturing process results in the loss of time and money, but
the risk of this can be minimised if some basic organisational
steps are followed, argues Brookwood's director...
The GEA Group has acquired the manufacturer of freeze dryers for
pharmaceutical products, STERIS, a unit of US-based STERIS
Corporation in a deal that aims to strengthen the group's Process
Engineering Division in the Process...
Boehringer Ingelheim and Slovenian company BIA Separations have
collaborated on a new separation and purification system that
should improve the production of plasmid DNA.
The marriage between US chemicals group Dynamic Synthesis and
French separations specialist Novasep has been completed, creating
what the new company claims is a unique company to serve the life
sciences industry.
GEA, a subsidiary of mg technologies, today announced that it has
acquired the business of Messo-Chemietechnik, which specialises in
crystallisation technologies for the biotechnology, pharmachem and
food industries.
France-based ProSim has introduced a comprehensive database of the
thermo-physicial properties of close to 2,000 pure compounds that
should be valuable for researchers working in process simulation.
In an unusual move, Finnish science park Medipolis has set up a new
Good Manufacturing Practice (GMP) pilot plant to take advantage of
the growing demand for biopharmaceutical production capacity.
Dowpharma has unveiled plans to consolidate its biopharmaceutical
custom process development activities to a single site in the US
that it says will make it easier to respond to its clients' needs.
German processing technology group GEA has announced new
acquisitions that will increase its offering to the food and pharma
industries, part of a new strategy to expand the business under
parent company mg technologies.
Radleys Discovery Technologies, a UK-based specialist in parallel
chemistry, has introduced a platform to speed up the purification
process after synthesis of multiple compounds.
The US FTC has taken issue with the merger between Aspen Technology
and Hyprotech in 2002, alleging that it gave the combined firm a
too-dominant position in process control software.
